Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
HYFT•Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the pharmaceuticals peer group is "buy".
Wall Street's median 12-month price target for MindWalk Holdings Corp is $5.00, about 283.1% above its Sept. 11 closing price of $1.31.
Quarterly results
Canada Bio-Native AI firm's fiscal Q1 revenue grew 21% year over year, while its net loss widened as sales and marketing expenses rose.
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q1 Revenue | C$3.80 mln | ||
| Q1 Loss Per Share | C$0.13 | ||
| Q1 Gross Profit | C$2.24 mln |
Outlook and financing
The company expects a shift to recurring, platform-based revenue as ReefIQ and LensAI enterprise deployments grow.
MindWalk said a US$30 mln credit facility commitment will support onboarding of enterprise clients and platform partnerships.
Margins and expense drivers
Gross margin expanded to 59%, up from 48% a year earlier.
The company said the wider net loss and higher operating expenses were due to planned investment in sales and marketing for the ReefIQ rollout. Co said commercial launch of the ReefIQ platform drove a shift toward recurring, platform-based revenue, while gross margin expanded as revenue grew and cost of sales held steady.
